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Abstract. Pure α- and β-anomers of O-mannosyl conjugates with 1-adamantamine and ferrocene amines 
were prepared. The sugar moiety in these glycoconjugates is connected to the amine by a chiral linker 
(methyl (R)-3-hydroxy-2-methyl propanoate and/or methyl (S)-3-hydroxy-2-methyl propanoate). The  
α-D-mannopyranosides with adamantane and ferrocene aglycon parts were tested using the hemaggluti-
nation assay (inhibition of the agglutination of guinea pig erythrocytes by type 1 fimbriated E. coli HB101 
(pPKl4)). All glycoconjugates showed inhibitory potencies in the mM range. 
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INTRODUCTION 
Research in the field of glycobiology has shown that 
molecular recognition involving carbohydrates and cell-
surface proteins (lectins) is of essential importance in 
many biological processes.1,2  
Among other biological processes, carbohydrate-
protein interactions play important roles in the cell and 
microbial adhesion. Adhesion of pathogenic organisms 
to host tissues is the initiation of the majority of infec-
tious diseases. It is often mediated by lectins present on 
the surface of the infectious organism that combines 
with complementary sugars on the host surface.3 One 
type of receptor-ligand interaction is that of the most 
common family of bacterial adhesins, mannose-specific 
type 1 fimbriae.4 In Escherichia coli, mannose-specific 
adhesion is mediated by the FimH adhesin at the tip of 
type 1 fimbriae. FimH has two domains, the mannose-
binding lectin domain and the fimbria-incorporating 
pilin domain which are connected by an interdomain 
linker peptide chain.5,6 
It is well known that many lectins in addition to 
the carbohydrate binding sites, possess hydrophobic 
binding sites, in particular around the site at which the 
aglycon will be localized upon carbohydrate-lectin 
complexation. Several studies were reported with large 
numbers of α-D-mannopyranosides with high-affinity 
ligands, some of them of significant inhibitory potency 
for E. coli type 1 adhesin. Almost all recent communi-
cations have been focused on glycoconjugate dendri-
mers which were found to bind with high affinity to 
FimH and prevent hemagglutination of red blood cells 
mediated by cross-linking of surface epitopes containing 
mannose.4,7–10 However, multivalent ligands are pre-
dicted to be poorly permeable to the GI tract and proba-
bly not amenable for oral dosing because of their large 
molecular weight and high polarity. Of all the reported 
monovalent FimH mannoside antagonists long chain 
alkyl and arylmannosides were shown to display the 
highest affinity possibly due to increased hydrophobic 
interactions within the binding pocket.11 Arylmannoside 
inhibitors of hemagglutination were first reported many 
years ago12,13 but very limited structure-activity relation-
ship studies followed.12,14 A recent study shows the 
importance of monovalent aromatic FimH mannoside 
antagonists designed for the clinical treatment of urinary 
tract infections.15 
In view of previous reports it seems of interest to 
explore the influence of monovalent FimH mannoside 
antagonists with structurally different aglycons on the 
resulting binding capacities. Therefore, we decided to 
study mannose conjugates with 1-adamantamine and 
ferrocene amines in order to compare the influence of 
bulky adamantane and aromatic ferrocene moieties on 
the inhibitory potencies aimed to preventing the ad-
hesion of E. coli to erythrocytes. Both aglycons are 
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hydrophobic and therefore when conjugated to man-
nose, potentially able to interact with lectin's hydro-
phobic binding sites.  
In continuation of our interest and research of mo-
nosaccharide conjugates,16 their enzymatic transforma-
tions17–20 and synthesis,21,22 especially of those with 
biological activity23 we now report the synthesis of 
series of mannose conjugates with 1-adamantamine and 
ferrocene amines. The newly synthesized compounds 
were subsequently submitted to the hemagglutination 
assay in order to explore their inhibitory potency  
towards type 1 fimbriated E. coli. Several drugs contain-
ing the adamantane moiety are currently commercially 
available. They are mostly used in the prevention of 
viral diseases and as drugs in the treatment of Parkinson 
disease.24 Among them 1-Adamantamine (amantadine) 
plays an important role since it inhibits the reproduction 
of influenza viruses.24,25 Some glycoconjugates of ada-
mantane are also used as drugs. The most often used 
one is gludantan, the adamantamine conjugate of glucu-
ronic acid, which is used as an antiviral agent as well as 
a drug in the treatment of Parkinson disease and depres-
sion.24 On the other hand conjugates of ferrocene with 
various biomolecules, e.g. amino acids, peptides, pro-
teins, DNA, RNA, PNA and carbohydrates play an 
important role in bioorganometallic chemistry. Stability 
of the ferrocenyl moiety in aqueous aerobic media and 
its favourable electrochemical properties make the  
derived bioorganometallics suitable for biological appli-
cation: bioanalysis, enzymology, biomimesis, catalysis, 
bioprobes, genosensors, novel therapeuticals, etc.26–31 






pyranosyl trichloroacetimidate (1α) was prepared as 
described previously.32 Ferrocenylamine and methyl 1'-
aminoferrocene-1-carboxylic acid were synthesized in 
the form of N-Boc protected derivatives (FcNHBoc, 33 
Boc-Fca-Ome34) by Curtius rearrangement of Fc-CON3 
and MeOOC-Fn-CON3 in tert-butyl alcohol. Ferrocenyl-
methylamine was freshly prepared by reduction of fer-
rocenecarboxamide with LiAlH4/THF.
35 Most of the 
chemical reagents used in syntheses were obtained from 
Fluka and Aldrich Corp. All solvents were purified 
using standard procedures. Column cromatography 
(solvents and proportions are given in the text) of ada-
mantane conjugates was performed on Merck silica gel 
60 (size 70–230 mesh ASTM) and TLC monitoring on 
Fluka silica gel (60 F 254) plates (0.25 mm). Visuali-
zation was effected mostly by use of UV light and/or by 
charring with H2SO4. Preparative TLC of ferrocene 
containing compounds was performed on silica gel 
using the mixture of diethyl ether/petroleum ether (φ = 
0.67) as eluents. Optical rotations were measured at 
room temperature using the Schmidt + Haensch Polar-
tronic NH8. NMR spectra were recorded using Bruker 
Avance spectrometer at 300 or 600 MHz. 
 
Hemagglutination Test 
Bacteria: pPK14 plasmid, bearing genes for Escherichia 
coli type 1 fimbriae36 was a generous gift from Dr. Per 
Klemm, Department of Systems Biology, Technical 
University of Denmark. The plasmid was electroporated 
into E. coli HB101 strain competent cells (defective in 
type 1 fimbriae production) followed by selection of the 
transformed cells (HB101 (pPKl4)) on LB/amp plates. 
A single colony was transferred into 500 mL of LB/amp 
media and bacterial culture was grown overnight at  
37 °C (about 15 h). E. coli HB101 (pPKl4) cells were 
harvested by centrifugation (2000 rpm, 15 min at 4 °C), 
washed twice with PBS buffer (8 g NaCl, 0.2 g KCl, 
1.44 g Na2HPO4×2H2O and 0.2 g KH2PO4 were dis-
solved in distilled water up to 1 L total volume, pH = 
7.0) and resuspended in the same buffer in approximate 
concentration of 10 mg mL–1 wet weight.4 Produced E. 
coli HB101 (pPKl4) cells having expressed type 1 fim-
briae were kept at 4 °C (no longer than two days) prior 
to the usage in hemagglutination assay. Guinea pig 
blood (5 mL) was freshly isolated and stabilized by 3.8 % 
sodium citrate (1 mL). After centrifugation (2000 rpm, 
10 min) packed erythrocytes (4 mL) were obtained. The 
sediment of erythrocytes was carefully suspended in 
PBS (4 mL) and this procedure of centrifugation and 
washing of the sediment was repeated twice. Packed 
erythrocytes (4 mL) were suspended in PBS (76 mL) 
and stored at 4 °C. Hemagglutination tests were per-
formed in V-shaped 96 well microtiter plates (Nunc). 
Sugar derivatives were suspended in distilled deionized 
water and serially diluted solutions (10 μL) were mixed 
with bacteria suspension (10 μL) in wells. After 10 min 
guinea pig erythrocytes (10 μL) were added and eryt-
hrocyte agglutination was read after 10 min at room 
temperature.  
 
Synthesis of O-Mannosylated Derivatives of (R)- and 
(S)-Methyl 3-hydroxy-2-methylpropanoates (2α, 2β, 3α 
and 3β) 
General Procedure. (R)-(+)- or (S)-(–)-Methyl 3-hydr-
oxy-2-methylpropanoate (151.07 μL, 1.37 mmol, 1.6 
eq.) was suspended in dry CH2Cl2 (2 mL) at 0 °C under 
N2 and BF3×Et2O was added (277.52 μL, 2.19 mmol, 1 
eq.). Glycosyl trichloroacetimidate 1α (1.5 g, 2.19 
mmol) was suspended in dry CH2Cl2 (2 mL) and then 
added dropwise within 15 min after which the reaction 
mixture was stirred for the additional 2.5 h and moni-
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tored by TLC (diethyl ether/petroleum ether, φ = 0.50). 
Iced 1 M NaHCO3 was added and the resulting mixture 
extracted with diethyl ether. Organic layers were 
washed with water and dried over Na2SO4. After filtra-
tion, the organic layer was concentrated in vacuo and 
the residue was purified by column chromatography on 
silica gel (diethyl ether/petroleum ether, φ = 0.50). The 
products were isolated as anomeric pale yellow oil mix-
tures 2α, 2β (1.023 g, 73 %) and 3α, 3β (953 mg, 68 %).  
The anomeric mixtures 2α, 2β and 3α, 3β were 
then rechromatographied to isolate pure anomers of 
each derivative. All analytical data for 2α and 2β were 
identical to those desribed in our previous paper.23 
(S)-Methyl 3-(2,3,4,6-tetra-O-benzyl-α-D-mannopyrano-
syloxy)-2-methylpropanoate (3α). [α]D +34.8º (c 1.32, 
CHCl3); Rf = 0.37 (diethyl ether/petroleum ether, φ = 
0.50). 1H NMR (CDCl3) δ / ppm: 7.37–7.16 (m, 20H, 
H–Ar), 4.86 (d, J1,2 = 1.6 Hz, 1H, H-1), 4.85 (d, Jgem = 
10.72 Hz, 1H, CH2Ph), 4.75–4.52 (m, 6H, 3 CH2Ph), 
4.51 (d, Jgem = 10.99 Hz, 1H, CH2Ph), 3.98 (app t, J = 
9.43 Hz, J = 9.43 Hz, 1H, H-4), 3.82 (dd, J2,3 = 2.91 Hz, 
J3,4 = 9.39 Hz, 1H, H-3), 3.87–3.83 (m, 1H, H-2), 3.78 
(dd, J5,6a = 5.40 Hz, J6a,6b = 11.02 Hz, 1H, H-6a), 3.73–
3.70 (m, 3H, OCH2, H-6b), 3.61 (s, 3H, OCH3), 3.45–
3.42 (m, 1H, H-5), 2.73–2.67 (m, 1H, CH), 1.13 (d, J = 
7.10 Hz, 3H, CH3). 
13C NMR (CDCl3) δ / ppm: 174.69 
(C=O), 138.52, 138.45, 138.42, 138.34 (C–Ar), 128.35–
127.26 (CH–Ar), 97.88 (C-1), 80.01, 74.80, 74.73, 71.99 
(C-2–5), 74.85, 73.26, 72.55, 72.16 (CH2Ph), 69.20 (C-6), 
68.95 (OCH2), 51.64 (OCH3), 39.65 (CH), 13.80 (CH3). 
Anal. Calcd. mass fraction of elements, w / %, for 
C39H44O8 are: C 73.10, H 6.92, found: C 73.01, H 6.86. 
(S)-Methyl 3-(2,3,4,6-tetra-O-benzyl-β-D-manno-pyra-
nosyloxy)-2-methylpropanoate (3β). [α]D –43.2º (c 0.44, 
CHCl3); Rf = 0.30 (diethyl ether/petroleum ether, φ = 
0.50). 1H NMR (CDCl3) δ / ppm: 7.45–7.15 (m, 20H, 
H–Ar), 4.94 (d, Jgem = 12.56 Hz, 1H, CH2Ph), 4.90 (d, 
Jgem = 10.85 Hz, 1H, CH2Ph), 4.80 (d, Jgem = 12.51 Hz, 
1H, CH2Ph), 4.66–4.37 (m, 4H, 2 CH2Ph), 4.52 (d, Jgem = 
10.79 Hz, 1H, CH2Ph), 4.39 (s, 1H, H-1), 4.03–3.98 (m, 
1H, H-4), 3.89–3.82 (m, 2H, H-2, H-3), 3.79–3.72 (m, 
2H, OCH2), 3.68 (s, 3H, OCH3), 3.67–3.61 (m, 1H,  
H-6a), 3.50–3.41 (m, 2H, H-5, H-6b), 2.91–2.80 (m, 
1H, CH), 1.18 (d, J = 7.18 Hz, 3H, CH3). 
13C NMR 
(CDCl3) δ / ppm: 175.44 (C=O), 138.62, 138.37, 138.26, 
137.08 (4 C–Ar), 128.38–127.35 (CH–Ar), 102.00 (C1), 
82.13, 75.89, 74.77, 73.18 (C-2–5), 75.13, 73.63, 73.42, 
71.76 (4 CH2Ph), 71.31 (C-6), 69.55 (OCH2), 51.73 
(OCH3), 40.27 (CH), 13.96 (CH3). 
Anal. Calcd. mass fraction of elements, w / %, for 
C39H44O8 are: C 73.10, H 6.92, found: C 72.96, H 6.88. 
 
Synthesis of O-Mannosylated Propionic Acids (4α, 4β, 
5α and 5β) 
General Procedure. To a solution of pure anomer of 
each ester derivative 2 and 3 (100 mg, 0.156 mmol) in 
dioxane (1 mL) 10 equivalents of 1 M NaOH was added 
and the reaction mixture was stirred for 24 h at 40 °C 
and monitored by TLC (C6H6/EtOAc, φ = 0.67). Reac-
tion mixtures were then neutralized with 0.5 M HCl (pH = 
3.5) and saturated brine was added. Mixtures were  
extracted with diethyl ether and organic layers dried 
over Na2SO4. After filtration, the organic layer was 
concentrated in vacuo and the residues purified by col-
umn chromatography on silica gel (CHCl3/MeOH, φ = 
0.90). 
All the NMR data for (R)-3-(2,3,4,6-tetra-O-
benzyl-α-D-mannopyranosyloxy)-2-methylpropanoic acid 
4α (91.9 mg, 94 %) and (R)-3-(2,3,4,6-tetra-O-benzyl-β-
D-mannopyranosyloxy)-2-methylpropanoic acid 4β (81.1 
mg, 83 %) are identical to those previously reported.23 
(S)-3-(2,3,4,6-Tetra-O-benzyl-α-D-mannopyranosyloxy)- 
2-methylpropanoic acid (5α). Pale yellow oil (83.1 mg, 
85 %); [α]D +16.9º (c 0.42, CHCl3); Rf = 0.59 (CHCl3/ 
methanol, φ = 0.90). 1H NMR (CDCl3) δ / ppm: 7.36–
7.16 (m, 20H, H–Ar), 4.89 (d, J1,2 = 1.59 Hz, 1H, H-1), 
4.88 (d, Jgem = 11.07 Hz, 1H, CH2Ph), 4.74–4.54 (m, 
6H, 3 CH2Ph), 4.50 (d, Jgem = 10.83 Hz, 1H, CH2Ph), 
3.96 (app t, J = 9.25 Hz, J = 9.26 Hz, 1H, H-4), 3.88 
(dd, J2,3 = 2.57 Hz, J3,4 = 9.29 Hz, 1H, H-3), 3.87–3.84 
(m, 1H, H-2), 3.78–3.73 (m, 4H, OCH2, H-6a, H-6b), 
3.66–3.62 (m, 1H, H-5), 3.08–3.03 (m, 1H, CH), 1.29 
(d, J = 7.06 Hz, 3H, CH3). 
13C NMR (CDCl3) δ / ppm: 
179.00 (C=O), 138.45, 138.39, 138.36, 138.32 (4 C–Ar), 
128.49–127.36 (CH–Ar), 98.03 (C-1), 79.99, 74.83, 
74.81, 72.04 (C-2–5), 75.13, 73.33, 72.67, 72.25  
(4 CH2Ph), 69.18 (C-6), 68.84 (OCH2), 39.59 (CH), 
13.70 (CH3).  
Anal. Calcd. mass fraction of elements, w / %, for 
C38H42O8 are: C 72.82, H 6.75, found: C 72.70, H 6.63. 
(S)-3-(2,3,4,6-Tetra-O-benzyl-β-D-mannopyranosyloxy)- 
2-methylpropanoic acid (5β). Pale yellow oil (75.3 mg, 
77 %); [α]D –41.1º (c 0.56, CHCl3); Rf = 0.49 (CHCl3/ 
methanol, φ = 0.90). 1H NMR (CDCl3) δ / ppm: 7.43–
7.15 (m, 20H, H–Ar), 4.93 (d, Jgem = 12.55 Hz, 1H, 
CH2Ph), 4.88 (d, Jgem = 10.98 Hz, 1H, CH2Ph), 4.80 (d, 
Jgem = 12.47 Hz, 1H, CH2Ph), 4.51 (d, Jgem = 10.67 Hz, 
1H, CH2Ph), 4.40 (s, 1H, H-1), 4.64–4.38 (m, 4H, 2 
CH2Ph), 4.02–3.97 (m, 1H, H-4), 3.89–3.82 (m, 2H,  
H-2, H-3), 3.81–3.63 (m, 3H, H-6a, OCH2), 3.50–3.43 
(m, 2H, H-5, H-6b), 2.91–2.80 (m, 1H, CH), 1.20 (d, J = 
7.09 Hz, 3H, CH3).
13C NMR (CDCl3) δ / ppm: 179.41 
(C=O), 138.51, 138.19, 138.19, 138.04 (4 C–Ar), 128.40–
127.39 (CH–Ar), 101.95 (C-1), 82.11, 75.77, 74.71, 73.29  
(C-2–5), 75.12, 73.75, 73.42, 71.63 (4 CH2Ph), 71.39  
(C-6), 69.50 (OCH2), 40.28 (CH), 13.75 (CH3).  
Anal. Calcd. mass fraction of elements, w / %, for 
C38H42O8 are: C 72.82, H 6.75, found: C 72.64, H 6.59. 
 
Synthesis of AMA Mannopyranosides (7α, 7β, 8α and 8β) 
General Procedure. To a solution of pure anomer of 
each carboxylic acid derivative 7–10 (100 mg, 0.16 
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mmol) in dry CH2Cl2 at 0 °C EDC×HCl (25.4 mg, 0.208 
mmol, 1.3 eq.) previously mixed with Et3N (28.8 μL) 
was added. The mixtures were then stirred for 0.5 h at 
the same temperature. HOBt (21.6 mg, 0.16 mmol, 1 eq.) 
was added next and the mixtures were left stirring for 
additional 2 h. During that time the temperature was 
allowed to gradually warm up to room temperature. 
AMA×HCl (150.1 mg, 0.8 mmol) previously mixed 
with Et3N (110.9 μL) was added next and the reactions 
were left stirring overnight. After the neutralization with 
0.5 M HCl (pH = 3.5) the mixtures were extracted with 
CH2Cl2, combined organic layers washed with saturated 
NaHCO3 and dried over Na2SO4. After filtration, the 
organic layers were concentrated in vacuo and the resi-
dues purified by column chromatography on silica gel 
(C6H6/EtOAc, φ = 0.67). 
(R)-N-(Adamantan-1-yl)-3-(2,3,4,6-tetra-O-benzyl-α-D-
mannopyranosyloxy)-2-methylpropanamide (7α). Pale 
yellow oil (69.3 mg, 57 %); [α]D –7.8º (c 1.03, CHCl3); 
Rf = 0.44 (C6H6/EtOAc, φ = 0.67). 
1H NMR (CDCl3)  
δ / ppm: 7.36–7.16 (m, 20H, H–Ar), 5.62 (s, 1H, N–H), 
4.90 (d, Jgem = 10.87 Hz, 1H, CH2Ph), 4.88 (s, 1H, H-1), 
4.75–4.54 (m, 6H, 3 CH2Ph), 4.51 (d, Jgem = 11.04 Hz, 
1H, CH2Ph), 3.91–3.64 (m, 7H, H-2, H-3, H-4, H-6a,  
H-6b, OCH2), 3.54–3.49 (m, 1H, H-5), 2.53–2.42 (m, 1H, 
CH), 1.99 (s, 3H, 3 CH-AMA), 1.88 (s, 6H, 3 CH2–AMA), 
1.60 (s, 6H, 3 CH2–AMA), 0.97 (d, J = 6.94 Hz, 3H, CH3). 
13C NMR (CDCl3) δ / ppm: 173.64 (C=O), 138.54, 138.38, 
138.17, 138.05 (4 C–Ar), 128.47–127.31 (CH–Ar), 99.54 
(C-1), 80.23, 75.08, 74.57, 71.93 (C-2–5), 74.84, 73.58, 
72.59, 72.20 (4 CH2Ph), 71.99 (C-6), 69.90 (OCH2),  
51.62 (C–N), 42.09 (CH), 41.54 (CH2–AMA), 36.30  
(CH2–AMA), 29.37 (CH-AMA), 14.16 (CH3) ppm.  
Anal. Calcd. mass fraction of elements, w / %, for 
C48H57NO7 are: C 75.86, H 7.56, N 1.84, found: C 
75.74, H 7.52; N,1.94. 
(R)-N-(Adamantan-1-yl)-3-(2,3,4,6-tetra-O-benzyl-β-D-
mannopyranosyloxy)-2-methylpropanamide (7β). Pale 
yellow oil (66.9 mg, 55 %); [α]D –59.4º (c 0.32, CHCl3); 
Rf = 0.37 (C6H6/EtOAc, φ = 0.67). 
1H NMR (CDCl3)  
δ / ppm: 7.46–7.17 (m, 20H, H–Ar), 5.80 (s, 1H, N–H), 
4.95 (d, Jgem = 12.46 Hz, 1H, CH2Ph), 4.90 (d, Jgem = 11.01 
Hz, 1H, CH2Ph), 4.83 (d, Jgem = 12.34 Hz, 1H, CH2Ph), 
4.55 (d, Jgem = 11.78 Hz, 1H, CH2Ph), 4.65–4.47 (m, 4H, 2 
CH2Ph), 4.39 (s, 1H, H-1), 4.06–4.00 (m, 1H, H-4), 3.93–
3.87 (m, 2H, H-2, H-3), 3.85–3.71 (m, 2H, OCH2), 3.53–
3.42 (m, 3H, H-5, H-6a, H-6b), 2.55–2.44 (m, 1H, CH), 
1.97 (s, 3H, 3 CH-AMA), 1.93 (s, 6H, 3 CH2–AMA), 1.59 
(s, 6H, 3 CH2–AMA), 1.16 (d, J = 7.08 Hz, 3H, CH3).  
13C NMR (CDCl3) δ / ppm: 173.02 (C=O), 138.64, 138.29, 
138.25, 138.08 (4 C–Ar), 128.44–127.34 (CH–Ar), 101.34 
(C-1), 82.22, 75.86, 74.82, 74.02 (C-2–5), 75.13, 73.99, 
73.47, 71.81 (4 CH2Ph), 71.60 (C-6), 69.62 (OCH2),  
51.62 (C–N), 41.57 (CH), 41.43 (CH2–AMA), 36.33  
(CH2–AMA), 29.39 (CH-AMA), 14.25 (CH3).  
Anal. Calcd. mass fraction of elements, w / %, for 
C48H57NO7 are: C 75.86, H 7.56, N 1.84, found: C 
75.76, H 7.50, N 1.89. 
(S)-N-(Adamantan-1-yl)-3-(2,3,4,6-tetra-O-benzyl-α-D-
mannopyranosyloxy)-2-methylpropanamide (8α). Pale 
yellow oil (69.3 mg, 57 %); [α]D +11.9º (c 0.42, CHCl3); 
Rf = 0.46 (C6H6/EtOAc, φ = 0.67). 
1H NMR (CDCl3)  
δ / ppm: 7.38–7.14 (m, 20H, H–Ar), 5.32 (s, 1H, N–H), 
4.90–4.50 (m, 8H, 4 CH2Ph), 4.87 (s, 1H, H-1), 4.01 
(app t, J = 9.32 Hz, J = 9.40 Hz, 1H, H-4), 3.84 (dd, J2,3 = 
2.69 Hz, J3,4 = 9.36 Hz, 1H, H-3), 3.80–3.70 (m, 5H, 
OCH2, H-2, H-6a, H-6b), 3.33–3.30 (m, 1H, H-5), 2.36–
2.31 (m, 1H, CH), 1.95 (s, 3H, 3 CH-AMA), 1.90 (s, 
6H, 3 CH2–AMA), 1.58 (s, 6H, 3 CH2–AMA), 1.05 (d, 
J = 6.88 Hz, 3H, CH3). 
13C NMR (CDCl3) δ / ppm: 173.10 
(C=O), 138.71, 138.49, 138.39, 138.28 (4 C–Ar), 
128.33–127.32 (CH–Ar), 97.84 (C-1), 80.18, 74.85, 
74.59, 71.91 (C-2–5), 74.82, 73.28, 72.52, 72.22 (4 
CH2Ph), 70.01 (C-6), 69.07 (OCH2), 51.62 (C–N), 41.79 
(CH), 41.67 (CH2–AMA), 36.32 (CH2–AMA), 29.38 
(CH-AMA), 14.12 (CH3). 
Anal. Calcd. mass fraction of elements, w / %, for 
C48H57NO7 are: C 75.86, H 7.56, N 1.84, found: C 
75.75, H 7.59, N 1.89. 
(S)-N-(Adamantan-1-yl)-3-(2,3,4,6-tetra-O-benzyl-β-D-
mannopyranosyloxy)-2-methylpropanamide (8β). Pale 
yellow oil (68.1 mg, 56 %); [α]D –23.0º (c 0.43, CHCl3); 
Rf = 0.31 (C6H6/EtOAc, φ = 0.67). 
1H NMR (CDCl3)  
δ / ppm: 7.46–7.17 (m, 20H, H–Ar), 5.80 (s, 1H, N–H), 
4.95 (d, Jgem = 12.47 Hz, 1H, CH2Ph), 4.90 (d, Jgem = 
11.00 Hz, 1H, CH2Ph), 4.83 (d, Jgem = 12.34 Hz, 1H, 
CH2Ph), 4.55 (d, Jgem = 11.78 Hz, 1H, CH2Ph), 4.65–
4.47 (m, 4H, 2 CH2Ph), 4.39 (s, 1H, H-1), 4.06–4.00 (m, 
1H, H-4), 3.93–3.87 (m, 2H, H-2, H-3), 3.83–3.70 (m, 
2H, OCH2), 3.53–3.42 (m, 3H, H-5, H-6a, H-6b), 2.55–
2.44 (m, 1H, CH), 1.97 (s, 3H, 3 CH–AMA), 1.92 (s, 
6H, 3 CH2–AMA), 1.59 (s, 6H, 3 CH2–AMA), 1.16 (d, 
J = 7.08 Hz, 3H, CH3). 
13C NMR (CDCl3) δ / ppm: 
173.02 (C=O), 138.64, 138.30, 138.25, 138.08  
(4 C–Ar), 128.44–127.34 (CH–Ar), 101.34 (C-1), 82.22, 
75.86, 74.82, 74.02 (C-2–5), 75.13, 73.99, 73.47, 71.80 
(4 CH2Ph), 71.60 (C-6), 69.62 (OCH2), 51.62 (C–N), 
41.57 (CH), 41.43 (CH2–AMA), 36.32 (CH2–AMA), 
29.38 (CH-AMA), 14.25 (CH3). 
Anal. Calcd. mass fraction of elements, w / %, for 
C48H57NO7 are: C 75.86, H 7.56, N 1.84, found: C 
75.76, H 7.55, N 1.94. 
 
Synthesis of Ferrocene Mannopyranosides (11α, 11β, 
12 α, 12 β, 13 α and 13 β) 
General Procedure. A suspension of 1.5 mmol of 
FcNHBoc or MeOOCFcNHBoc in ethyl acetate was 
cooled to 0 °C and treated with gaseous HCl for 2 h. 
After stirring at room temperature for 4 h, mixture was 
evaporated in vacuo to dryness to leave yellow solid 
hydrochloride. This salt was treated with Et3N in dry 
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CH2Cl2 (pH ≈ 8) and added to solution of 1 mmol of 
mannopyranoside carboxylic acids 4α, β activated in a 
similar way as described in general procedure for the-
preparation of AMA glycoconjugates. After stirring for 
72 h at room temperature, the mixture was washed 
thrice with saturated solution of NaHCO3, 10 % 
aqueous solution of citric acid and H2O, then dried over 
Na2SO4 and evaporated in vacuo. The residue was puri-
fied by TLC on silica gel (CH2Cl2/EtOAc, φ = 0.83) 
giving anomeric mixtures which were rechromographed 
using diethyl ether/petroleum ether (φ = 0.67) to leave 
pure anomers as orange/yellow oils (11α, 11β, 12α and 
12β). In a similar way free FcCH2NH2 (obtained by 
reduction of FcCONH2 by LiAlH4 in THF) was coupled 
with mannopyranosides 4α, β giving after TLC purifica-
tion conjugates 13α and 13β. 
(R)-N-Ferrocenyl-3-(2,3,4,6-tetra-O-benzyl-α-D-manno-
pyranosyloxy)-2-methylpropanamide (11α). Orange oil 
(57.3 mg, 59 %); [α]D +28.9º (c 2.7, CHCl3); Rf = 0.64 
(diethyl ether/petroleum ether, φ = 0.67). 1H NMR 
(CDCl3) δ / ppm: 7.69 (s, 1H, N–H), 7.32–7.25 (m, 20H, 
H–Ar), 4.89–4.60 (m, 7H, CH2Ph), 4.57 (s, 2H, HFc), 
4.22 (d, Jgem = 10.81 Hz, 1H, CH2Ph), 4.35 (br s, 1H,  
H-1), 4.09 (s, 5H, HFc), 4.03 (d, J1,2 = 1.77 Hz, 1H,  
H-2), 3.99 (d, J3,4 = 9.33 Hz, 1H, H-4), 3.92 (d, J2,3 = 
2.46 Hz, 1 H. H-3), 3.88–3.83 (m, 2H, OCH2), 3.77–
3.72 (m, 2H, H-6a, H-6b), 3.47–3.42 (m, 1H, H-5), 
2.81–2.76 (m, 1H, CH), 0.99 (d, J = 6.72 Hz, 3H, CH3) 
13C NMR (CDCl3) δ / ppm: 173.22 (C=O), 138.31, 
138.28, 138.20, 137.39 (4 C–Ar), 128.51–127.63  
(CH–Ar), 101.68 (C-1), 94.74 (C-1, Fc), 79.80, 75.60, 
75.50, 72.01 (C-2–5), 74.57, 74.41, 74.04, 73.04 (4 
CH2Ph), 72.51 (C-6), 69.19, 64.51, 63.91, 61.11, 60.95 
(CFc), 70.82 (OCH2), 42.25 (CH), 14.51 (CH3).  
Anal. Calcd. mass fraction of elements, w / %, for 
C48H51NO7Fe are: C 71.2, H 6.35, N 1.73, found: C 
71.35, H 6.38, N 1.76. 
(R)-N-Ferrocenyl-3-(2,3,4,6-tetra-O-benzyl-β-D-manno- 
pyranosyloxy)-2-methyl-propanamide (11β). Orange oil 
(24.9 mg, 77 %); [α]D –27.5º (c 0.8, CHCl3); Rf =  
0.51 (diethyl ether/petroleum ether, φ = 0.67). 1H NMR 
(CDCl3) δ / ppm: 7.68 (s, 1H, N–H), 7.46–7.17 (m, 20H, 
H–Ar), 4.94–4.55 (m, 6H, CH2Ph), 4.57 (s, 2H, HFc), 
4.53 (s, 2H, HFc), 4.52–4.49 (m, 2H, CH2Ph), 4.43 (s, 
1H, H-1), 4.08 (s, 5H, HFc), 3.94 (d, J2,3 = 2.55 Hz, 1H, 
H-2), 3.90–3.87 (m, 2H, H-3, H-4), 3.78–3.72 (m, 2H, 
OCH2), 3.61–3.58 (m, 2H, H-6a, H-6b), 3.52–3.48 (m, 
1H, H-5), 2.69–2.66 (m, 1H, CH), 1.20 (d, J = 7.33 Hz, 
3H, CH3). 
13C NMR (CDCl3) δ / ppm: 172.14 (C=O), 
138.47, 138.32, 138.22, 138.05 (4 C–Ar), 128.43–
127.53 CH–Ar), 100.89 (C-1), 95.21 (C-1, Fc), 82.26, 
75.80, 74.88, 74.15 (C-2–5), 75.17, 74.09, 73.37, 71.92 
(4 CH2Ph), 71.27 (C-6), 69.22, 64.44, 64.39, 61.48, 
61.38 (CFc), 69.65 (OCH2), 40.97 (CH), 13.97 (CH3).  
Anal. Calcd. mass fraction of elements, w / %, for 
C48H51NO7Fe are: C 71.2, H 6.35, N 1.73, found: C 
71.37, H 6.37, N 1.75. 
(R)-N-1'-Methoxycarbonylferrocenyl-3-(2,3,4,6-tetra-O-
benzyl-α-D-manno-pyranosyloxy)-2-methylpropan-amide 
(12α). Orange oil (101.9 mg, 98 %); [α]D –1.4º  
(c 2.1, CHCl3); Rf = 0.61 (diethyl ether/petroleum ether, 
φ = 0.67). 1H NMR (CDCl3) δ / ppm: 7.65 (s, 1H, N–H), 
7.33–7.17 (m, 20H, H–Ar), 4.95–4.88 (m, 3H, CH2Ph), 
4.69 (s, 2H, HFn), 4.62–4.57 (m, 3H, CH2Ph), 4.54  
(s, 2H, HFn), 4.51–4.49 (m, 2H, CH2Ph), 4.46 (s, 1H, 
H-1), 4.29 (s, 2H, HFn), 4.07 (app t, J = 8.58 Hz, J = 
9.00 Hz, 1H, H-4), 3.96 (d, J2,3 = 2.67 Hz, 1H, H-3), 
3.93 (s, 1H, H-2), 3.90 (s, 2H, HFn), 3.87–3.79 (m, 2H, 
OCH2), 3.78–3.76 (m, 2H, H-6a, H-6b), 3.75 (s, 3H, 
COCH3), 3.65–3.59 (m, 1H, H-5), 2.74–2.67 (m, 1H, 
CH), 1.25 (d, J = 7.62 Hz, 3H, CH3). 
13C NMR (CDCl3) 
δ / ppm: 172.31 (C=O), 171.69 (COCH3), 138.54, 138.28, 
138.22, 138.07 (4 C–Ar), 128.41–127.36 (CH–Ar), 100.94 
(C-1), 95.96 (C-1, Fn), 82.25, 75.81, 74.84, 74.20 (C-2–5), 
75.14, 74.09, 73.36, 71.87 (4 CH2Ph), 71.26 (C-6), 
72.60, 70.98, 66.24, 66.06, 62.76, 62.72 (CFn), 71.51 
(C-1', Fn), 69.59 (OCH2), 51.54 (COCH3), 40.96 (CH), 
13.81 (CH3).  
Anal. Calcd. mass fraction of elements, w / %, for 
C50H53NO9Fe are: C 69.20, H 6.16, N 1.61, found: C 
69.09, H 6.25, N 1.62. 
(R)-N-1'-Methoxycarbonylferrocenyl-3-(2,3,4,6-tetra-O-
benzyl-β-D-manno-pyranosyloxy)-2-methylpropan-amide 
(12β). Orange oil (25.1 mg, 72 %); [α]D +16.3º  
(c 0.8, CHCl3); Rf = 0.78 (diethyl ether/petroleum ether, 
φ = 0.67). 1H NMR (CDCl3) δ / ppm: 7.53 (s, 1H,  
N–H), 7.29–7.20 (m, 20H, H–Ar), 4.90–4.57 (m, 5H, 
CH2Ph), 4.85 (d, Jgem = 10.73 Hz, 1H, CH2Ph), 4.70–
4.69 (m, 2H, HFn), 4.62 (d, Jgem = 11.58 Hz, 1H, 
CH2Ph), 4.58 (s, 2H, HFn), 4.49 (d, Jgem = 11.16 Hz, 
1H, CH2Ph), 4.46 (d, J1,2 = 1.38 Hz, 1H, H-1), 4.28 (s, 
2H, HFn), 3.97 (d, J3,4 = 9.06 Hz, 1H, H-4), 3.94 (pt, 
2H, HFn), 3.92–3.91 (m, 1H, H-3), 3.89–3.84 (m, 3H, 
H-2, OCH2), 3.81–3.78 (m, 2H, H-6a, H-6b), 3.74 (s, 
3H, COCH3), 3.53–3.50 (m, 1H, H-5), 2.75–2.73 (m, 
1H, CH), 1.03 (d, J = 6.96 Hz, 3H, CH3). 
13C NMR 
(CDCl3) δ / ppm: 172.77 (C=O), 171.42 (COCH3), 
137.77, 137.68, 137.06, 137.04 (4 C–Ar), 127.99–
127.07 (CH–Ar), 100.51 (C-1), 95.11 (C-1, Fn), 79.21, 
74.81, 72.60, 72.33 (C-2–5), 74.17, 73.41, 72.90, 72.41 
(4 CH2Ph), 71.83 (C-6), 71.53, 70.62, 70.31, 66.05, 
65.59, 62.08, 61.9 (CFn), 70.99 (C-1', Fn), 70.01 
(OCH2), 51.05 (COCH3), 41.61 (CH), 13.93 (CH3).  
Anal. Calcd. mass fraction of elements, w / %, for 
C50H53NO9Fe (Mr = 867.83)·½ CH2Cl2 are: C 66.63, H 
5.98, N 1.54, found: C 66.65, H 6.02, N 1.56. 
(R)-N-Ferrocenylmethyl-3-(2,3,4,6-tetra-O-benzyl-α-D-
mannopyranosyloxy)-2-methylpropanamide (13α): 
Yellow oil (76.1 mg, 77 %); [α]D –27.5º (c 2.0, CHCl3); 
Rf = 0.70 (diethyl ether/petroleum ether, φ = 0.67).  
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1H NMR (CDCl3) δ / ppm: 7.37–7.27 (m, 20H, H–Ar), 
6.12 (app t, J = 4.79 Hz, J = 4.65 Hz, 1H, N–H), 4.87–
4.45 (m, 8H, CH2Ph), 4.48 (s, 1H, H-1), 4.20–4.13 (m, 
2H, HFc), 4.08 (s, 5H, HFc), 4.06 (s, 2H, HFc), 4.01 (d, 
J2,3 = 2.37 Hz, 1H, H-3), 3.94–3.93 (m, 2H, CH2Fc), 
3.80–3.76 (m, 4H, H-4, H-2, OCH2), 3.72–3.68 (m, 2H, 
H-6a, H-6b), 3.55–3.50 (m, 1H, H-5), 2.60–2.53 (m, 
1H, CH), 1.01 (d, J = 7.02 Hz, 3H, CH3). 
13C NMR 
(CDCl3) δ / ppm: 173.40 (C=O), 137.99, 137.95, 
137.83, 137.52 (4 C–Ar), 127.86–127.07 (CH–Ar), 
99.34 (C-1), 83.85 (C-1, Fc), 79.70, 74.67, 74.44, 71.42 
(C-2–5), 74.47, 72.99, 72.23, 71.71 (4 CH2Ph), 71.67 
(C-6), 68.10, 68.08, 68.04, 67.75, 67.52 (CFc), 69.42 
(OCH2), 40.91 (CH), 38.49 (CH2Fc), 13.84 (CH3).  
Anal. Calcd. mass fraction of elements, w / %, for 
C49H53NO7Fe are: C 71.44, H 6.48, N 1.7, found: C 
71.54, H 6.52, N 1.73. 
(R)-N-Ferrocenylmethyl-3-(2,3,4,6-tetra-O–benzyl-β-D-
manno-pyranosyloxy)-2-methylpropanamide (13β): Yellow 
oil (20.4 mg, 62 %); [α]D –25.5º (c 1.0, CHCl3); Rf = 
0.57 (diethyl ether/petroleum ether, φ = 0.67). 1H NMR 
(CDCl3) δ / ppm: 7.42–7.16 (m, 20H, H–Ar), 6.29 (app 
t, J = 4.75 Hz, J = 4.26 Hz, 1H, N–H), 4.88–4.50 (m, 
7H, CH2Ph), 4.76 (d, Jgem = 12.21 Hz, 1H, CH2Ph), 4.36 
(s, 1H, H-1), 4.11 (s, 2H, HFc), 4.08 (s, 5H, HFc), 4.06 
(s, 2H, HFc), 4.04–4.02 (m, 3H, H-4, CH2Fc), 3.85 (d, 
J2,3 = 2.73 Hz, 1H, H-3), 3.82–3.74 (m, 3H, H-2, OCH2), 
3.65–3.55 (m, 2H, H-6a, H-6b), 3.50–3.46 (m, 1H, H-5), 
2.64–2.57 (m, 1H, CH), 1.20 (d, J = 7.11 Hz, 3H, CH3). 
13C NMR (CDCl3) δ / ppm: 172.88 (C=O), 138.21, 137.86, 
137.76, 137.61 (4 C–Ar), 128.05–126.99 (CH–Ar), 100.68 
(C-1), 84.31 (C-1, Fc), 81.73, 75.32, 74.34, 73.70 (C-2–5), 
74.61, 73.59, 72.93, 71.19 (4 CH2Ph), 70.85 (C-6), 68.05, 
68.00, 67.93, 67.55, 67.46 (CFc), 69.16 (OCH2), 40.53 
(CH), 38.27 (CH2Fc), 13.92 (CH3).  
Anal. Calcd. mass fraction of elements, w / %, for 
C49H53NO7Fe are: C 71.44, H 6.48, N 1.7, found: C 
71.56, H 6.54, N 1.68. 
 
Debenzylation of AMA and Ferrocene Conjugates 
General Procedure. To a solution of pure anomer of 
each AMA 7 and 8 (100 mg, 0.132 mmol) and Fc con-
jugate 11–13 (100 mg) in CH2Cl2 (5 mL) 50 mg of 10 % 
Pd/C and 20 mL of CH3OH was added. The mixtures 
were subjected to hydrogen atmosphere under 4 bars at 
room temperature and stirred for 24 h. Then they were 
filtered over a celite bed and the filtrates concentrated in 
vacuo. The residues were purified by column chromato-
graphy on silica-gel (CH3CN/H2O, φ = 0.83) and the 
compounds 9, 10, and 14–16 were obtained. 
(R)-N-(Adamantan-1-yl)-3-α-D-mannopyranosyloxy-2-
methylpropanamide (9α). Pale yellow crude foam (49.4 
mg, 94 %); [α]D +17.2º (c 0.64, CH3OH); Rf = 0.58 
(acetonitrile/H2O, φ = 0.83). 1H NMR (CD3OD): δ / 
ppm = 7.30 (s, 1H, N–H), 4.71 (d, J1,2 = 1.47 Hz, 1H,  
H-1), 3.85–3.80 (m, 1H, H-3), 3.83 (dd, J6b,5 = 1.84 Hz, 
J6a,6b = 11.68 Hz, H-6b), 3.76 (dd, J1,2 = 1.62 Hz, J2,3 = 
3.02 Hz, 1H, H-2), 3.72–3.45 (m, 6H, H-3, H-4, H-5,  
H-6a, OCH2), 2.65–2.53 (m, 1H, CH), 2.02 (br s, 9H,  
3 CH-AMA, 3 CH2–AMA), 1.71 (s, 6H, 3 CH2–AMA), 
1.01 (d, J = 6.94 Hz, 3H, CH3). 
13C NMR (CD3OD):  
δ / ppm = 176.73 (C=O), 102.28 (C-1), 74.72, 72.67, 
72.13, 68.62 (C-2–5), 71.55 (C-6), 62.94 (OCH2), 52.86  
(C–N), 42.82 (CH), 42.44 (CH2–AMA), 37.56  
(CH2–AMA), 30.97 (CH-AMA), 14.64 (CH3).  
Anal. Calcd. mass fraction of elements, w / %, for 
C20H33NO7 are: C 60.13, H 8.33, N 3.51, found: C 
59.94, H 8.23, N 3.65. 
(R)-N-(Adamantan-1-yl)-3-β-D-mannopyranosyloxy-2-
methylpropanamide (9β). Pale yellow crude foam (46.3 
mg, 88 %); [α]D –45.7º (c 0.70, CH3OH); Rf = 0.53 
(acetonitrile/H2O, φ = 0.83). 
1H NMR (CD3OD): δ / 
ppm = 7.26 (s, 1H, N–H), 4.20 (d, J1,2 = 0.63 Hz, 1H,  
H-1), 3.96–3.93 (m, 1H, H-4), 3.87 (dd, J6a,5 = 2.34 Hz, 
J6a,6b = 11.78 Hz, 1H, H-6a), 3.84 (d, J2,3 = 3.06 Hz, 1H, 
H-2), 3.71 (dd, J6b,5 = 6.02 Hz, J6a,6b = 11.79 Hz, 1H,  
H-6b), 3.56–3.51 (m, 2H, OCH2), 3.45 (dd, J2,3 = 3.22 
Hz, J3, 4 = 9.39 Hz, 1H, H-3), 3.22–3.19 (m, 1H, H-5), 
2.63–2.57 (m, 1H, CH), 2.04 (s, 3H, 3 CH-AMA), 2.03 
(s, 6H, 3 CH2–AMA), 1.72 (s, 6H, 3 CH2–AMA), 1.07 
(d, J = 6.96 Hz, 3H, CH3). 
13C NMR (CD3OD): δ / ppm = 
176.64 (C=O), 101.29 (C-1), 78.35, 75.29, 72.48, 68.65 
(C-2–5), 72.29 (C-6), 62.92 (OCH2), 52.93 (C–N), 42.43 
(CH2–AMA), 42.36 (CH), 37.57 (CH2–AMA), 30.98 
(CH–AMA), 14.79 (CH3).  
Anal. Calcd. mass fraction of elements, w / %, for 
C20H33NO7 are: C 60.13, H 8.33, N 3.51, found: C 
60.02, H 8.28, N 3.63. 
(S)-N-(Adamantan-1-yl)-3-α-D-mannopyranosyloxy-2-
methylpropanamide (10α). Pale yellow crude foam 
(47.3 mg, 90 %); [α]D +46.6º (c 0.88, CH3OH); Rf = 
0.61 (acetonitrile/H2O, φ = 0.83). 
1H NMR (CD3OD):  
δ / ppm = 7.27 (s, 1H, N–H), 4.74 (d, J1,2 = 1.46 Hz, 1H, 
H-1), 3.83 (dd, J6b,5 = 2.38 Hz, J6a,6b = 11.74 Hz, 1H,  
H-6b), 3.80 (app t, J = 9.26 Hz, J = 9.27 Hz, 1H, H-4), 
3.77 (dd, J1,2 = 1.67 Hz, J2,3 = 3.25 Hz, 1H, H-2), 3.67 
(dd, J2,3 = 3.30 Hz, J3,4 = 9.40 Hz, 1H, H-3), 3.72–3.61 
(m, 3H, OCH2, H-6a), 3.55–3.52 (m, 1H, H-5),  
2.62–2.57 (m, 1H, CH), 2.03 (br s, 9H, 3 CH-AMA,  
3 CH2–AMA), 1.72 (s, 6H, 3 CH2–AMA), 1.04 (d, J = 
6.93 Hz, 3H, CH3). 
13C NMR (CD3OD): δ / ppm = 
176.53 (C=O), 101.38 (C-1), 74.44, 72.77, 72.24, 68.52 
(C-2–5), 70.71 (C-6), 62.87 (OCH2), 52.90 (C–N), 
42.50 (CH2–AMA), 42.41 (CH), 37.57 (CH2–AMA), 
30.97 (CH–AMA), 14.69 (CH3).  
Anal. Calcd. mass fraction of elements, w / %, for 
C20H33NO7 are: C 60.13, H 8.33, N 3.51, found: C 
60.00, H 8.21, N 3.69. 
(S)-N-(Adamantan-1-yl)-3-β-D-mannopyranosyloxy-
2-methylpropanamide (10β). Pale yellow crude foam 
(45.7 mg, 87 %); [α]D –9.0º (c 0.512, CH3OH); Rf = 
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0.59 (acetonitrile/H2O, φ = 0.83). 
1H NMR (CD3OD):  
δ / ppm = 7.25 (s, 1H, N–H), 4.48 (d, J1,2 = 0.74 Hz, 1H, 
H-1), 3.88 (dd, J6a,5 = 2.36 Hz, J6a,6b = 11.75 Hz, 1H, H-
6a), 3.83 (d, J2,3 = 3.17 Hz, 1H, H-2), 3.80–3.77 (m, 1H, 
H-4), 3.71 (dd, J6b,5 = 5.91 Hz, J6a,6b = 11.76 Hz, 1H, H-
6b), 3.64–3.53 (m, 2H, OCH2), 3.43 (dd, J2,3 = 3.22 Hz, 
J3,4 = 9.39 Hz, 1H, H-3), 3.22–3.19 (m, 1H, H-5), 2.63–
2.57 (m, 1H, CH), 2.04 (s, 3H, 3 CH-AMA), 2.03 (s, 
6H, 3 CH2–AMA), 1.71 (s, 6H, 3 CH2–AMA), 1.02 (d, 
J = 7.00 Hz, 3H, CH3). 
13C NMR (CD3OD): δ / ppm = 
176.89 (C=O), 102.29 (C-1), 78.34, 75.32, 72.53, 68.62 
(C-2–5), 73.14 (C-6), 62.88 (OCH2), 52.92 (C–N), 
42.96 (CH), 42.42 (CH2–AMA), 37.58 (CH2–AMA), 
30.98 (CH-AMA), 14.45 (CH3).  
Anal. Calcd. mass fraction of elements, w / %, for 
C20H33NO7 are: C 60.13, H 8.33, N 3.51, found: C 
60.05, H 8.20, N 3.65. 
(R)-N-Ferrocenyl-3-α-D-mannopyranosyloxy-2-methyl-
propanamide (14α). Yellow solid (51.0 mg, 91 %); [α]D 
+33º (c 0.6, CH3OH/CHCl3 (φ = 0.50)); Rf = 0.41 (ace-
tonitrile/H2O, φ = 0.83). 
1H NMR (DMSO-d6): δ / ppm = 
9.29 (s, 1H, N–H), 4.64 (d, J1,2 = 0.72 Hz, 1H, H-1), 
4.60 (s, 2H, HFc), 4.53 (s, 2H, HFc), 4.18 (d, J2,3 = 3.86 
Hz, 1H, H-2 ), 4.08 (s, 5H, HFc), 3.97–3.92 (m, 2H,  
H-3, H-4), 3.63–3.56 (m, 2H, OCH2), 3.56–3.48 (m, 2H, 
H-6a, H-6b), 3.41–3.40 (m, 1H, H-5), 2.67–2.61 (m, 
1H, CH), 0.99 (d, J = 6.52 Hz, 3H, CH3). 
13C NMR 
(DMSO-d6): δ / ppm = 172.88 (C=O), 101.09 (C-1), 
95.94 (C-1, Fc), 74.41, 71.44, 70.67, 70.57 (C-2–5), 
69.95 (C-6), 69.27, 67.43, 64.26, 64.05, 61.04 (CFc), 
61.71 (OCH2), 45.44 (CH), 14.33 (CH3).  
Anal. Calcd. mass fraction of elements, w / %, for 
C20H27NO7Fe are: C 53.47, H 6.06, N 3.12, found: C 
53.58, H 6.03, N 3.10. 
(R)-N-Ferrocenyl-3-β-D-mannopyranosyloxy-2-methy-
lpropanamide (14β). Yellow solid (48.8 mg, 87 %); [α]D 
–4.4º (c 0.46, CH3OH/CHCl3, φ = 0.50); Rf = 0.34  
(acetonitrile/H2O (φ = 0.83)). 
1H NMR (DMSO-d6): δ / 
ppm = 9.25 (s, 1H, N–H), 4.74 (d, J1,2 = 0.90 Hz, 1H,  
H-1), 4.59 (s, 2H, HFc), 4.44 (s, 2H, HFc), 4.24 (d, J2,3 
= 3.84 Hz, 1H, H-2), 4.10 (s, 5H, HFc), 3.93–3.90 (m, 
1H, H-4), 3.89 (d, J3,4 = 8.58 Hz, 1H, H-3), 3.67–3.66 
(m, 2H, OCH2), 3.44–3.43 (m, 2H, H-6a, H-6b), 3.30–
3.29 (m, 1H, H-5), 2.66–2.65 (m, 1H, CH), 1.05 (d, J = 
6.60 Hz, 3H, CH3). 
13C NMR (DMSO-d6): δ / ppm = 
172.24 (C=O), 99.81 (C-1), 95.46 (C-1, Fc), 77.59, 73.69, 
70.44, 70.38 (C-2–5), 70.26 (C-6), 68.77, 67.14, 63.60, 
60.64, 60.57 (CFc), 61.37 (OCH2), 45.00 (CH), 14.45 (CH3).  
Anal. Calcd. mass fraction of elements, w / %, for 
C20H27NO7Fe are: C 53.47, H 6.06, N 3.12, found: C 
53.37, H 6.11, N 3.08. 
(R)-N-1'-Methoxycarbonylferrocenyl-3-α-D-manno-pyra-
nosyloxy-2-methyl-propanamide (15α): Orange solid 
(48.7 mg, 83 %); [α]D +172º (c 0.9, CH3OH/CHCl3, φ = 
0.50); Rf = 0.45 (acetonitrile/H2O, φ = 0.83). 
1H NMR 
(DMSO-d6): δ / ppm = 7.54 (s, 1H, N–H), 4.68 (s, 2H, 
HFc), 4.67 (s, 1H, H-1), 4.52 (s, 2H, HFc), 4.39 (s, 2H, 
HFc), 4.35 (s, 1H, H-4), 4.06–3.91 (m, 2H, H-3, H-2), 
3.78 (s, 2H, HFc), 3.68–3.49 (m, 4H, OCH2, H-6a,  
H-6b), 3.59 (s, 3H, COCH3), 3.03–2.93 (m, 1H, H-5), 
2.76–2.66 (m, 1H, CH), 1.18 (d, J = 6.70 Hz, 3H, CH3). 
13C NMR (DMSO-d6): δ / ppm = 172.98 (C=O), 168.24 
(COCH3), 100.09 (C-1), 97.14 (C-1, Fn), 77.50, 73.97, 
73.62, 70.90 (C-2–5), 70.62 (C-6), 70.43, 70.11, 67.07, 
66.90 (CFn), 69.98 (C-1', Fn), 69.42 (OCH2), 51.44 
(COCH3), 41.38 (CH), 13.19 (CH3).  
Anal. Calcd. mass fraction of elements, w / %, for 
C22H29NO9Fe are: C 52.09, H 5.76, N 2.76, found: C 
52.17, H 5.71, N 2.81. 
(R)-N-1'-Methoxycarbonylferrocenyl-3-β-D-manno-
pyranosyloxy-2-methylpropanamide (15β). Orange solid 
(43.1 mg, 74 %); [α]D +13.3º (c 0.9, CH3OH); Rf =0.40 
(DCM/CH3OH, φ = 0.90). 
1H NMR (DMSO-d6): δ / 
ppm = 7.45 (s, 1H, N–H), 4.77 (s, 1H, H-1), 4.75 (s, 2H, 
HFc), 4.45 (s, 2H, HFc), 4.14 (d, J3,4 = 9.35 Hz, 1H,  
H-4), 4.05 (s, 2H, HFc), 3.90–3.87 (m, 4H, H-2, H-3, 
OCH2), 3.76 (s, 3H, COCH3), 3.67 (s, 2H, HFc), 3.38–
3.34 (m, 3 H H-6a, H-6b), 3.18–3.08 (m, 1H, H-5), 
2.79–2.69 (m, 1H, CH), 1.16 (d, J = 6.17 Hz, 3H, CH3). 
13C NMR (DMSO-d6): δ = 173.03 (C=O), 169.99 
(COCH3), 100.14 (C-1), 91.87 (C-1, Fn), 77.47, 73.97, 
73.92, 70.87 (C-2–5), 69.54 (C-6), 70.19, 70.09, 66.89, 
66.71 (CFn), 69.76 (C-1', Fn), 69.12 (OCH2), 51.33 
(COCH3), 35.09 (CH), 14.58 (CH3).  
Anal. Calcd. mass fraction of elements, w / %, for 
C22H29NO9Fe are: C 52.09, H 5.76, N 2.76, found: C 
52.20, H 5.81, N 2.78. 
(R)-N-Ferrocenylmethyl-3-α-D-mannopyranosyloxy-2-
methylpropanamide (16α). Yellow solid (49.2 mg,  
88 %); [α]D +20.6º (c 0.5, CH3OH); Rf = 0.51 (aceto-
nitrile/H2O (φ = 0.83)). 
1H NMR (DMSO-d6): δ / ppm = 
8.01 (s, 1H, N–H), 4.49 (s, 1H, H-1), 4.15 (s, 2H, HFc), 
4.14 (s, 5H, HFc), 4.13 (s, 2H, HFc), 4.06–4.02 (m, 4H, 
H-2, H-3, OCH2), 3.97–3.96(m, 3H, H-4, CH2Fc), 3.78–
3.75 (m, 1H, H-5), 3.61–3.52 (m, 2H, H-6a, H-6b), 
2.62–2.57 (m, 1H, CH), 1.04 (d, J = 7.01 Hz, 3H, CH3). 
13C NMR (DMSO-d6): δ / ppm = 173.13 (C=O), 97.76 
(C-1), 86.32 (C-1, Fc), 78.37, 75.52, 74.06, 71.18 (C-2–5), 
72.22 (C-6), 68.36, 67.53, 67.44, 67.14, 67.04 (CFc), 69.22 
(OCH2), 39.95 (CH), 37.29 (CH2Fc), 14.62 (CH3).  
Anal. Calcd. mass fraction of elements, w / %, for 
C21H29NO7Fe are: C 54.44, H 6.31, N 3.02, found: C 
54.56, H 6.29, N 3.03. 
(R)-N-Ferrocenylmethyl-3-β-D-mannopyranosyloxy-2-
methylpropanamide (16β): Yellow solid (51.0 mg,  
91 %); [α]D –8.8º (c 0.4, CH3OH/CHCl3, φ = 0.50); Rf = 
0.45 (acetonitrile/H2O, φ = 0.83). 
1H NMR (DMSO-d6): 
δ / ppm = 8.00 (app t, J = 5.70 Hz, J = 5.95 Hz, 1H,  
N–H), 4.39 (s, 1H, H-1), 4.25–4.22 (m, 1H, H-3), 4.17–
4.16 (m, 2H, HFc), 4.15 (s, 5H, HFc), 4.14 (s, 2H, HFc), 
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4.10 (d, J2,3 = 2.34 Hz, 1H, H-2), 4.07 (s, 2H, CH2Fc), 
4.05–4.03 (m, 1H, H-4), 4.02–4.01 (m, 2H, OCH2), 
3.95–3.91 (m, 2H, H-6a, H-6b), 3.86–3.83 (m, 1H,  
H-5), 2.64–2.58 (m, 1H, CH), 1.01 (d, J = 6.89 Hz, 3H, 
CH3). 
13C NMR (DMSO-d6): δ / ppm = 173.08 (C=O), 
99.97 (C-1), 86.18 (C-1, Fc), 77.54, 73.93, 73.66, 70.41 
(C-2–5), 70.53 (C-6), 68.32, 67.66, 67.64, 67.18, 67.12 
(CFc), 69.72 (OCH2), 39.58 (CH), 37.39 (CH2Fc), 14.61 
(CH3).  
Anal. Calcd. mass fraction of elements, w / %, for 
C21H29NO7Fe are: C 54.44, H 6.31, N 3.02, found: C 
54.59, H 6.27, N 2.99. 
 
RESULTS AND DISCUSSION 
Synthesis of Glycoconjugates 
The synthesis of O-mannosyl conjugates of 1-ada-
mantamine (AMA) using O-glycosidically bonded chir-
al linkers is reported. Linkers of (R)- and (S)- configura-
tion were used on purpose in order to study the influ-
ence of linkers configuration on the inhibitory potency 
of conjugates in the hemagglutination test. 
Scheme 1 shows the reaction sequence starting 
from α-D-mannopyranosyl trichloroacetimidate 1α to 
the key intermediates 4 and 5 used for the synthesis of 
AMA (9, 10) and Fc (14–16) glycoconjugates. Trichloro-
acetimidate 1α was prepared as an active intermediate in 
the base-treated (NaH) reactions of O-benzylated man-
nose with trichloroacetonitrile at 0 °C in dichloro-
methane.32 O-Mannosylation of (R)- and (S)-methyl  
3-hydroxy-2-methylpropanoates was promoted by the 
catalytic amount of boron trifluoride diethyl etherate 
(BF3×Et2O) in dichloromethane at 0 °C. These trichloro-
acetimidate-mediated O-glycosylations gave anomeric 
mixtures of the corresponding O-glycosides 2, 3 (68–73 
%). α/β Ratios for O-mannosides 2 and 3 were found to 
be approximately 2:1. Since the non-participating pro-
tecting group was at the C-2 position, SN2-type reaction 
could occur leading to β-anomers. Such inversion was 
also assisted by the use of the weak Lewis acid catalyst 
at lower temperatures. On the other hand, α-mannosides 
are thermodynamically more stable glycosylation prod-
ucts because of the strong anomeric effect. α,β-Glyco-
sides 2 and 3 were readily separated by column chroma-
tography on silica gel using diethyl ether/petroleum 
ether (φ = 0.50) as the eluent of choice giving pure 
anomers 2α, 3α and 2β, 3β in moderate overall 
yields. 
The hydrolysis of methyl esters of each anomer 2 
and 3 was performed by saponification using 1 M  
sodium hydroxide in dioxane leading to 77–94 % of 
acids 4 and 5 (Scheme 1). 
The next step was the activation of the free car-
boxyl group and condensation with AMA. To achieve 
the most efficient procedure several methods were ex-
plored (Sheme 2).  
The first approach was the synthesis of an active 
N-hydroxysuccinimide ester (HOSu) 6 as a good acylat-
ing agent for the reaction with AMA.23 Condensation of 
AMA with the ester 6 gave the glycoconjugate 7 in  
83 % yield (Scheme 2). The pentafluorophenyl ester 
was also prepared, but the condensation with AMA 
unfortunately failed. Second strategy included carbo-
diimide-mediated synthesis: in situ activation of car-
boxyl carbon and amide bond formation using 
 
Scheme 1. i) (R)-methyl 3-hydroxy-2-methyl propionate or (S)-methyl 3-hydroxy-2-methyl propionate, BF3×Et2O/CH2Cl2, 0 ºC;
ii) 1. – separation of α- and β- anomers by column chromatography on silica gel, diethyl ether/petroleum ether (φ = 0.50), 2. – 1 M









































Scheme 2. i) EDC×HCl, HOSu, CH2Cl2, rt, (78%); ii) 
AMA×HCl/Et3N, rt, (83 %); iii) DCC/HOBt/AMA×HCl/Et3N, 
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DCC/HOBt,37 DCC/DMAP38 or EDC×HCl/HOBt gave 
in all cases the desired product 7 (Scheme 2). In this 
context the activation by EDC×HCl was the best me-
thod because the by-product (water-soluble urea deriva-
tive) can be more easily removed. Since the first ap-
proach includes two-step synthesis, less demanding 
EDC-mediated coupling was chosen for amide bond 
formation. Glycoconjugates 7 and 8 were obtained in 
good yields (55–66 %) in just one step starting from 
pure α- or β-anomers of acids 4 and 5 as shown in 
Scheme 3. 
Debenzylation of compounds 7 and 8 gave the de-
sired AMA conjugates 9 and 10 (87–94 %). Benzyl 
deprotection was performed by classic hydrogenolysis 
with 10 % Pd on charcoal in methanol. 
Preliminary hemagglutination tests with AMA 
conjugates showed that the linker configuration does not 
influence the results. Therefore, further syntheses of 
ferrocene glycoconjugates were performed by using the 
linker of only one configuration (R). We chose three 
representative types of ferrocene derivatives (which are 
usually preserved as N-Boc protected derivatives):  
(i) ferrocenylamine (FcNH2), (ii) methyl 1'-amino-ferro-
cene-1-carboxylate (MeOOCFcNHBoc) whose hete-
roannular ester subsistent of the flexible metallocene 
core could act as an additional site for binding to lec-
tins,4 and (iii) ferrocenylmethylamine (FcCH2NH2) 
which elongates the aliphatic linker in mannose-
ferrocene bioconjugates increasing the number of possi-
ble conformations of these molecules. 
In the ferrocene chemistry (because of the sensi-
tivity of the metallocene core) the general methods 
for the preparation of amides from carboxylic acids 
are performed either via carbonyl chlorides or by 
EDC/HOBt method. In our recent papers in the field 
of ferrocene containing oligopeptides (especially 
compounds of the type X-(AA)n-Fca-(AA)m-COOMe; 
m, n = 0,1,2…; X = Ac, Boc, Bn)33,39–43 the very suc-
cessful method was the latter. Therefore, this proce-
dure was applied for the synthesis of mannosides  
11–13. Contrary to the previously described method 
for the preparation of AMA glycosides (Scheme 1) 
the separation step of anomeric products was per-
formed following the reaction of the mannoside acids 
mixture 4α,β with ferrocene amines (the ferrocene 
compounds are yellow to orange coloured which 
simplifies their chromatographic purification). Thus, 
after hydrolysis of anomeric mixtures of esters 2α,β 
(Scheme 1) acids 4α,β were obtained in 90 % yields. 
Activation of 4α,β was performed by using 
EDC/HOBt method. Conjugation with free ferrocene 
amines (obtained by in situ deprotection of their  
N-Boc derivatives) produced the bioorganometallics 
11α,β–13α,β as shown in Scheme 4. Their TLC sepa-
ration on silica gel using diethyl ether/petroleum 
ether (φ = 0.67) as eluent gave analytically pure  
α- (59–98 %) and β- anomers (62–77 %) which were 
hydrogenolyzed (analogously to the procedure used 
in AMA preparations) to debenzylated conjugates 
14–16 in almost quantitative yields. 
 
































Scheme 3. i) 1. – EDC×HCl/Et3N/CH2Cl2, 0 ºC, 2. – HOBt, 0 ºC, 3. – FcNHBoc and MeOOCFcNHBoc/EtOAc/HCl (g)/Et3N or
FcCH2NH2/CH2Cl2, rt, 4. – TLC separation on silica gel, diethyl ether/petroleum ether (φ = 0.67); ii) H2 (4 bar)/(Pd/C (10%))/




























11a, 11b   n = 0, R = H
12a, 12b   n = 0, R = COOMe
13a, 13b   n = 1, R = H
4a, b
ii)
14a, 14b   n = 0, R = H
15a, 15b   n = 0, R = COOMe
16a, 16b   n = 1, R = H
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Inhibition Hemagglutination Tests of  
α-D-Mannopyranosides 
The influence of different aglycon moieties (adaman-
tane and ferrocene) on inhibitory potencies of manno-
side conjugates was explored, in order to reveal binding 
potencies toward mannose specific lectin.  
The results of our testings are in accord with pre-
viously reported studies of specificity of type 1 fim-
briae)7 which showed that mannosyl moieties should be 
of α-configuration for good binding to the lectin. There-
fore, compounds 9, 10, 14–16 that showed inhibition in 
hemagglutination tests were of α-configuration and their 
activities were calculated relative to α-D-manno-
pyranoside. Hydrophobic moieties in inhibitor mole-
cules add to the overall affinity toward the specific 
lectin. This may also be due to the binding to subsites 
adjacent to the mannose-specific binding pocket. The 
tested compounds incorporate hydrophobic adamantane 
and ferrocene subunits in non-carbohydrate parts. To the 
best of our knowledge, they are the first examples of 
adamantane and ferrocene containing mannosides used 
in inhibition hemagglutination tests with type 1 fim-
briated E. coli HB101 (pPKl4). The results of these 
assays are listed in Table 1. They are semi-quantitative 
and higly reproducible. The inhibition titer (IT) denotes 
the lowest concentration at which agglutination of gui-
nea pig erythroytes by E. coli is no longer visible.  
Methyl α-D-glucopyranoside was used as the control 
compound and non-specific binding did not occur, as 
expected. All the compounds showed inhibitory poten-
cies in mM range. Ferrocene mannosides have 2.4 times 
lower IT value than adamantyl derivatives.  
These results can be explained by the pronounced 
aromatic character of the ferrocene core, which is ob-
viously much stronger bound to lectines than the ali-
phatic adamantane subunit. From the literature it is 
known that the potent inhibitor of type 1 fimbriae me-
diated adhesion, p-nitrophenyl α-D-mannoside (pNPMan), 
binds approximately 80 times better than methyl  
α-D-mannopyranoside.13 Apparently, planar aromatic 
moieties of inhibitor molecules contribute more to the 
binding than the three-dimensional metallocene part 




In conclusion, we have reported the synthesis of novel 
mannose conjugates with 1-adamantamine and ferro-
cene amines. Mannosides prepared in this work are first 
compounds with adamantane and ferrocene in the agly-
con part used in inhibition hemagglutination tests with 
type 1 fimbriated E. coli HB101 (pPKl4). They exhibit 
inhibitory potencies in the mM range. It was shown that 
ferrocene α-D-mannosides (14α–16α) were better inhi-
bitors of E. coli adhesion than their aliphatic AMA 
analogues (9α, 10α). This is most probably due to the 
aromatic character of the ferrocene core and comparable 
with the very active aralkyl α-D-mannosides.13 Further-
more, it can be concluded that neither the absolute con-
figuration of the linkers part nor structural changes 
introduced in ferrocene conjugates, influence the inhibi-
tory potencies of tested compounds. 
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SAŽETAK  
Sinteza i biološka aktivnost konjugata manoze s  
1-adamantaminom i ferocenskim aminima 
Rosana Ribić,a Monika Kovačević,b Vesna Petrović Peroković,a Ita Gruić-Sovulj,a 
Vladimir Rapićb i Srđanka Tomića 
aKemijski odsjek, Prirodoslovno-matematički fakultet, Sveučilište u Zagrebu,  
Horvatovac 102A, 10000 Zagreb, Hrvatska 
bZavod za kemiju i biokemiju, Prehrambeno-biotehnološki fakultet,Sveučilište u Zagrebu,  
Pierottijeva 6, 10000 Zagreb, Hrvatska 
Pripravljeni su čisti α- i β-anomeri O-manozilnih konjugata 1-adamantamina i ferocenskih amina. Šećerni i amins-
ki dijelovi molekula međusobno su povezani kiralnom poveznicom  (metil-(R)-3-hidroksi-2-metil propanoatom 
i/ili metil-(S)-3-hidroksi-2-metil propanoatom). α-D-manopiranozidni derivati s adamantanskim ili ferocenskim 
aglikonima biološki su testirani hemaglutinacijskim testom (inhibicijom aglutinacije eritrocita zamorčića s ispolje-
nim fimbrijama tipa 1 bakterije 1 E. coli HB101 (pPKl4)). Svi su glikokonjugati pokazali inhibitorna svojstva u 
mM rasponu. 
